DOI: 10.55524/ijircst.2021.9.4.16 | DOI URL: https://doi.org/10.55524/ijircst.2021.9.4.16
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (http://creativecommons.org/licenses/by/4.0)
Article Tools: Print the Abstract | Indexing metadata | How to cite item | Email this article | Post a Comment
Recombinant antibodies in last decade, engineering has arisen as the most promising options for creating, choosing, or synthesizing molecules for scientific investigations, therapeutics, and the medical establishment. In a wide variety of sectors, exciting outcomes have really been realized. Since the introduction of recombinant antibodies technology coupled with the capability of phage display selection. One such Mini Overview summarizes the key discoveries that by use of Salmonella and filaments phage as weapons for executing strong processes from huge collections, as well as the utilization of extracellular expression of mob segment as a special generation of antagonistic molecules with promise, led to the invention of this well-known approach. Therapeutic applications. It considers what the future may hold for these constantly changing technology.
 Á. M. Cuesta, N. Sainz-Pastor, J. Bonet, B. Oliva, and L. Álvarez-Vallina, “Multivalent antibodies: When design surpasses evolution,” Trends in Biotechnology. 2010.
 C. Sellmann et al., “Balancing selectivity and efficacy of bispecific Epidermal Growth Factor Receptor (EGFR) x c-MET antibodies and antibody- drug conjugates,” J. Biol. Chem., 2016.
 C. C. M. Ho et al., “‘Velcro’ engineering of high affinity CD47 Ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis,” J. Biol. Chem., 2015.
 H. Singh, A. D. Aggarwal, V. Kushwaha, P. K. Agarwal, R. Chawla, and S. S. Sandhu, “Study of fatal injuries sustained by car drivers in road traffic accidents,” J. Punjab Acad. Forensic Med. Toxicol., 2016.
 R. Singh et al., “Association of coronary risk factors among patients with acute coronary syndromes,” World Heart J., 2016.
 P. Singh et al., “Proprotein convertase subtilisin kexin 9 (PCSK9) and lipoprotein metabolism in relation to adverse birth outcome and future cardiometabolic risk,” World Heart Journal. 2016.
 R. Rastogi, V. Budhiraja, S. K. Jain, N. Sharma, R. Garg, and H. Nafees, “Morphological pattern of Crista terminalis, Musculi pectinati and Taenia sagittalis with applied significance,” J. Morphol. Sci., 2016.
 S. Khan, A. Srivastava, K. Junej, and R. Rani, “Diabetic foot wound care practices among patients visiting a tertiary care hospital in North India,” Indian J. Community Heal., 2016.
 A. Haroon and R. Gangal, “Study of railway fatalities in moradabad district,” J. Indian Acad. Forensic Med., 2016.
 A. Thakur, M. Huang, and L. G. Lum, “Bispecific antibody based therapeutics: Strengths and challenges,” Blood Reviews. 2018.
 A. Alibakhshi et al., “Targeted cancer therapy through antibody fragments-decorated nanomedicines,” Journal of Controlled Release. 2017.
 K. Kartikey et al., “Effects of oxidative stress on development of osteoporosis, carcinogenesis, atherosclerosis and brain degeneration,” World Heart J., 2016.
 S. Chandak and A. Kumar, “Can radiology play a role in early diagnosis of dengue fever?,” N. Am. J. Med. Sci., 2016.
 A. Agarwal, R. Rastogi, S. Agarwal, G. L. Meena, V. P. Singh, and Y. Gupta, “Armamentarium in women’s imaging,” J. Int. Med. Sci. Acad., 2016.
 V. Giuliano and C. Giuliano, “Imaging features of breast malignancy: Breast ultrasound and MR imaging correlation,” Clin. Imaging, 2013.
 A. Dadwal, A. Baldi, and R. Kumar Narang, “Nanoparticles as carriers for drug delivery in cancer,” Artificial Cells, Nanomedicine and Biotechnology. 2018.
 P. Chames and D. Baty, “Antibody engineering and its applications in tumor targeting and intracellular immunization,” FEMS Microbiology Letters. 2000.
 K. T. Xenaki, S. Oliveira, and P. M. P. van Bergen en Henegouwen, “Antibody or antibody fragments: Implications for molecular imaging and targeted therapy of solid tumors,” Front. Immunol., 2017.
 Y. Zhu, S. H. Choi, and K. Shah, “Multifunctional receptor-targeting antibodies for cancer therapy,” The Lancet Oncology. 2015.
 V. Leko and S. A. Rosenberg, “Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors,” Cancer Cell. 2020.
 H. F. Tsai, A. Trubelja, A. Q. Shen, and G. Bao, “Tumour-on-a-chip: Microfluidic models of tumour morphology, growth and microenvironment,” Journal of the Royal Society Interface. 2017.
 S. Krah, H. Kolmar, S. Becker, and S. Zielonka, “Engineering IgG-Like Bispecific Antibodies—An Overview,” Antibodies, 2018.
 Y. Chen, Y. Song, W. Du, L. Gong, H. Chang, and Z. Zou, “Tumor-associated macrophages: An accomplice in solid tumor progression,” Journal of Biomedical Science. 2019.
 J. J. Gomez-Pina and A. M. Flores-Azamar, “Wilms’ tumor,” Med. Interna Mex., 2019.
 K. Yuki, N. Cheng, M. Nakano, and C. J. Kuo, “Organoid Models of Tumor Immunology,” Trends in Immunology. 2020.
 O. Melaiu, V. Lucarini, L. Cifaldi, and D. Fruci, “Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors,” Frontiers in Immunology. 2020.
Assistant Professor, Department of Life Sciences, Vivekananda Global University, Jaipur, India
No. of Downloads: 7 | No. of Views: 284
Dr. A. Seshagiri Rao, V. Nagarjuna, M. Sivudu.
November 2022 - Vol 10, Issue 6
Dr. Satish Saini.
March 2022 - Vol 10, Issue 2
March 2022 - Vol 10, Issue 2